CRMD
Price
$11.21
Change
-$0.23 (-2.01%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
853.98M
43 days until earnings call
FULC
Price
$8.26
Change
+$0.91 (+12.38%)
Updated
Sep 24, 04:59 PM (EDT)
Capitalization
397.57M
49 days until earnings call
Interact to see
Advertisement

CRMD vs FULC

Header iconCRMD vs FULC Comparison
Open Charts CRMD vs FULCBanner chart's image
CorMedix
Price$11.21
Change-$0.23 (-2.01%)
Volume$21.31K
Capitalization853.98M
Fulcrum Therapeutics
Price$8.26
Change+$0.91 (+12.38%)
Volume$22.69K
Capitalization397.57M
CRMD vs FULC Comparison Chart in %
Loading...
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRMD vs. FULC commentary
Sep 25, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRMD is a Hold and FULC is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 25, 2025
Stock price -- (CRMD: $11.44 vs. FULC: $7.35)
Brand notoriety: CRMD and FULC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRMD: 84% vs. FULC: 46%
Market capitalization -- CRMD: $853.98M vs. FULC: $397.57M
CRMD [@Biotechnology] is valued at $853.98M. FULC’s [@Biotechnology] market capitalization is $397.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $97.36B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRMD’s FA Score shows that 1 FA rating(s) are green whileFULC’s FA Score has 1 green FA rating(s).

  • CRMD’s FA Score: 1 green, 4 red.
  • FULC’s FA Score: 1 green, 4 red.
According to our system of comparison, FULC is a better buy in the long-term than CRMD.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRMD’s TA Score shows that 4 TA indicator(s) are bullish while FULC’s TA Score has 6 bullish TA indicator(s).

  • CRMD’s TA Score: 4 bullish, 5 bearish.
  • FULC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FULC is a better buy in the short-term than CRMD.

Price Growth

CRMD (@Biotechnology) experienced а -1.29% price change this week, while FULC (@Biotechnology) price change was +0.68% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was +10.70%, and the average quarterly price growth was +54.52%.

Reported Earning Dates

CRMD is expected to report earnings on Nov 06, 2025.

FULC is expected to report earnings on Nov 12, 2025.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRMD($854M) has a higher market cap than FULC($398M). FULC YTD gains are higher at: 56.383 vs. CRMD (41.235). CRMD has higher annual earnings (EBITDA): 52.3M vs. FULC (-81.28M). FULC has more cash in the bank: 214M vs. CRMD (191M). CRMD has less debt than FULC: CRMD (435K) vs FULC (7.57M). CRMD has higher revenues than FULC: CRMD (121M) vs FULC (0).
CRMDFULCCRMD / FULC
Capitalization854M398M215%
EBITDA52.3M-81.28M-64%
Gain YTD41.23556.38373%
P/E Ratio14.67N/A-
Revenue121M0-
Total Cash191M214M89%
Total Debt435K7.57M6%
FUNDAMENTALS RATINGS
CRMD vs FULC: Fundamental Ratings
CRMD
FULC
OUTLOOK RATING
1..100
5810
VALUATION
overvalued / fair valued / undervalued
1..100
53
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
69100
SMR RATING
1..100
2597
PRICE GROWTH RATING
1..100
5537
P/E GROWTH RATING
1..100
98100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FULC's Valuation (23) in the null industry is in the same range as CRMD (53) in the Medical Specialties industry. This means that FULC’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as FULC (100) in the null industry. This means that CRMD’s stock grew similarly to FULC’s over the last 12 months.

CRMD's SMR Rating (25) in the Medical Specialties industry is significantly better than the same rating for FULC (97) in the null industry. This means that CRMD’s stock grew significantly faster than FULC’s over the last 12 months.

FULC's Price Growth Rating (37) in the null industry is in the same range as CRMD (55) in the Medical Specialties industry. This means that FULC’s stock grew similarly to CRMD’s over the last 12 months.

CRMD's P/E Growth Rating (98) in the Medical Specialties industry is in the same range as FULC (100) in the null industry. This means that CRMD’s stock grew similarly to FULC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRMDFULC
RSI
ODDS (%)
Bullish Trend 2 days ago
84%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
83%
Momentum
ODDS (%)
Bearish Trend 2 days ago
84%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 7 days ago
87%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 16 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
CRMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FULC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AIXXF18.200.98
+5.69%
Aixtron SE
LVMHF610.4313.11
+2.19%
LVMH-Moet Hennessy Louis Vuitton
TMTNF110.52N/A
N/A
Toromont Industries Ltd.
TYCB55.51-0.49
-0.88%
Calvin B. Taylor Bankshares, Inc.
SPST0.09N/A
-5.00%
Superstar Platforms, Inc

CRMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRMD has been loosely correlated with MURA. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if CRMD jumps, then MURA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRMD
1D Price
Change %
CRMD100%
+1.51%
MURA - CRMD
37%
Loosely correlated
+0.97%
HOTH - CRMD
30%
Poorly correlated
+6.70%
FULC - CRMD
30%
Poorly correlated
-1.34%
BTAI - CRMD
30%
Poorly correlated
-11.15%
HRMY - CRMD
29%
Poorly correlated
-1.08%
More

FULC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FULC has been loosely correlated with ADPT. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if FULC jumps, then ADPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FULC
1D Price
Change %
FULC100%
-1.34%
ADPT - FULC
48%
Loosely correlated
-0.07%
TRDA - FULC
45%
Loosely correlated
-3.60%
BEAM - FULC
45%
Loosely correlated
-2.79%
OCUL - FULC
44%
Loosely correlated
+0.41%
VRDN - FULC
42%
Loosely correlated
+0.05%
More